Oral anticoagulants for stroke prevention in atrial fibrillation: current status, special situations, and unmet needs
- 1 July 2015
- journal article
- review article
- Published by Elsevier BV in The Lancet
- Vol. 386 (9990), 303-310
- https://doi.org/10.1016/s0140-6736(15)60245-8
Abstract
No abstract availableThis publication has 51 references indexed in Scilit:
- Dabigatran adherence in atrial fibrillation patients during the first year after diagnosis: a nationwide cohort studyJournal of Thrombosis and Haemostasis, 2015
- SAMe-TT2R2 Score, Time in Therapeutic Range, and Outcomes in Anticoagulated Patients with Atrial FibrillationAmerican Journal Of Medicine, 2014
- Variations in Cause and Management of Atrial Fibrillation in a Prospective Registry of 15 400 Emergency Department Patients in 46 CountriesCirculation, 2014
- Adherence to dabigatran therapy and longitudinal patient outcomes: Insights from the Veterans Health AdministrationAmerican Heart Journal, 2014
- Edoxaban versus Warfarin in Patients with Atrial FibrillationNew England Journal of Medicine, 2013
- 2012 focused update of the ESC Guidelines for the management of atrial fibrillationEuropean Heart Journal, 2012
- Apixaban versus Warfarin in Patients with Atrial FibrillationNew England Journal of Medicine, 2011
- Rivaroxaban versus Warfarin in Nonvalvular Atrial FibrillationNew England Journal of Medicine, 2011
- Dabigatran versus Warfarin in Patients with Atrial FibrillationNew England Journal of Medicine, 2009
- Improving the quality of anticoagulation of patients with atrial fibrillation in managed care organizations: results of the managing anticoagulation services trialAmerican Journal Of Medicine, 2002